Letter to the FDA Opposing Approval of the Sleep Medicine Suvorexant
This letter was sent to the U.S. Food and Drug Administration (FDA) as a follow-up to our testimony at the May 22, 2013 meeting of the Peripheral and Central Nervous System Drugs Advisory Committee that voted in favor of approval of the dangerous sleep medicine, suvorexant. We again urge the FDA not to approve suvorexant because the drug’s long-lasting risks – both to patients and the general public – outweigh any short-term benefits on sleep.
July 29, 2013, FDA Response to Letter